Cytokine receptor like factor 2 (CRLF2)- overexpressing pediatric Precursor B- acute lymphoblastic leukemia : An approach towards individualized therapy / Asmaa Mohamed Atef Abdelrahman ; Supervised Nayera Hamdy Elshakankiry , Emad Nabil Ebeid , Eman Omar Rasekh
Material type:
- زيادة تعبير العامل المماثل للمستقبلات الخلوية-2 فى الأطفال المصابين بسرطان الدم الأولى ب الليمفاوى الحاد : نهج نحو العلاج الفردى [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.03.Ph.D.2020.As.C (Browse shelf(Opens below)) | Not for loan | 01010110081145000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.03.Ph.D.2020.As.C (Browse shelf(Opens below)) | 81145.CD | Not for loan | 01020110081145000 |
Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Clinical Pathology
Introduction: Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a neoplastic proliferation of lymphoblasts that has a gene expression profile similar to that of BCR-ABL1 positive B-ALL, but lacks the disease-defining Philadelphia chromosome. Growing evidence has proved that alterations in the cytokine receptor-like factor 2 gene (CRLF2)that result in CRLF2 overexpression associates with poor treatment outcomes thus highlighting a potentially important oncogenic mechanism in a subset of patients. The significant association of CRLF2 overexpression with JAK2 mutation suggests that these patients may benefit from future kinase inhibitor approaches. In addition, cell surface-expressed CRLF2 itself may be a potential target for anti-CRLF2 antibody based therapies
Issued also as CD
There are no comments on this title.